Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/28/2012

we generated $170.7 million in cash flow from operations and deployed $170.0 million to repurchase 9.2 million shares during 2011.

Looking ahead in 2012ViroPharma is reiterating its guidance for the year 2012 as a convenience to investors.  The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties.  For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2012, ViroPharma expects the following:

  • Worldwide net product sales are expected to be $600 to $660 million;
  • Net U.S. Cinryze sales are expected to be $310 to $330 million;
  • Net Vancocin sales are expected to be $260 to $310 million; and
  • Research and development (R&D) and selling, general and administrative (SG&A) expenses are expected to be $230 to $260 million.

  • Non-GAAP DisclosuresThe Company is reporting both GAAP net income  and non-GAAP adjusted results for the three and twelve months ended December 31, 2011 and 2010.   Non-GAAP adjusted net income is GAAP net income excluding (1) non-cash interest expense, (2) amortization related intangible assets acquired, (3) stock compensation expenses, and (4) certain non-recurring events. Non-GAAP adjusted diluted net income per share reflects the Non-GAAP adjusted net income, after the incremental effect of applying the "if converted" method of accounting to the senior convertible notes, and the diluted shares used in determining our GAAP diluted net income per share. A reconciliation between GAAP and non-GAAP adjusted measures is provided in the Selected Financial Information – Non-GAAP Financial Measures Reconciliation table included with this release. The Company believes that its presentation of historical non-GAAP financial measure
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. ViroPharma to Present at Three September Healthcare Conferences
    2. ViroPharma to Present at Three October Healthcare Conferences
    3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
    4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
    5. ViroPharma to Present at Three November Healthcare Conferences
    6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
    7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
    8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
    9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
    10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
    11. ViroPharma to Present at Two June Healthcare Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2014)... Research and Markets has announced the addition ... Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... pulp & paper industry. The report provides ... applications and industry chain structure. The enzyme for pulp ...
    (Date:8/27/2014)... Tris Pharma, a specialty pharmaceutical company focused ... it has been selected as an award winner in ... Awards for Excellence competition in the Business Expansion ... judges from SCORE (Counselors to America,s Small Business) and ... at a gala event to be held on October ...
    (Date:8/27/2014)... (PRWEB) August 27, 2014 After the ... reason that the next beverage craze is going to ... today that formulators can use Stress Relief energy pattern ... in the making of a beverage, including minerals, herbs ... stress-generated energy, channeling that power into rapid recovery and ...
    (Date:8/27/2014)... WriteResult, LLC – a premier provider of ePRO ... when it comes to meeting the needs of a ... their most recent study closeout on-time and with near ... writing platform to collect Patient Reported Outcomes electronically for ... data from a number of assessments including the IBS-Severity ...
    Breaking Biology Technology:Global Enzyme for Pulp & Paper Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
    ... for Cancer Research (OICR) announced today it has enhanced ... called the IPDC Fund. The augmented program is designed ... stage technologies. "In the face of declining ... to offer greater support for the most promising Ontario-based ...
    ... Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today ... 2011 Conference on Tuesday, March 15th at 3.30 PM ... Convention Centre, Milan, Italy.Bio Europe Spring 2011CTI Presentation: Tuesday, ... AM PSTRoom Yellow 2, Milano Convention Centre (MIC) Media ...
    ... This release is available in German . ... which make them promising candidates for optoelectronic components. However, ... or influence their optic and electronic properties. A team ... at the Technische Universitaet Muenchen and member of the ...
    Cached Biology Technology:Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program 2Ultra fast photodetectors out of carbon nanotubes 2
    (Date:8/27/2014)... it is related to ability that we already possess. ... melody more easily than learning how to hit a ... the Neural Basis of Cognition (CNBC)a joint program between ... a fundamental constraint in the brain that may explain ... the Aug. 28, 2014, issue of Nature , ...
    (Date:8/27/2014)... of Utah biologist agan Sekercioglu, who campaigns to save ... highest science prize, which is similar to the U.S. ... researchers picked for 2014 the top awards by TUBITAK, ... researchers won the Science Award and two including ... to the Science Award but for scientists who are ...
    (Date:8/27/2014)... what is described by the Volunteer Wildfire Services of ... Cape provincial government warned residents in certain parts of ... veld fires. A high veld fire danger rating ... coast in the Great Kei and Mnquma area. ... thunderstorms. The thunderstorms bring lightning strikes and subsequent ...
    Breaking Biology News(10 mins):Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3University of Utah biologist wins Turkey's top science prize 2
    ... scientists have received new funding for a research program ... economically feasible. The project is based on the serendipitous ... fish cages in Puerto Rico by the thousands. The ... fascinating habits such as their tendency to crawl in ...
    ... mussels and oysters are important vehicles for the ... undercooked. Vibrio species, including human pathogens, are particularly ... even after cleaning procedures, thus representing a potential ... are well known to affect the persistence of ...
    ... during the summer in Alaska waters, is one of the ... in the 1800s has now left us with only a ... different species from right whales seen in the North Atlantic ... areas and ecological parameters critical to the survival of this ...
    Cached Biology News:New project aims to make large-scale lobster farms feasible 2New project aims to make large-scale lobster farms feasible 3Edible bivalves as a source of human pathogens: signals between vibrios and the bivalve host. 2Habitat use by North Pacific right whales, Eubalaena japonica, in the Bering Sea and Gulf of Alaska 2
    Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
    Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
    Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
    RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
    Biology Products: